{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T22:01:40Z","timestamp":1786658500724,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":673,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1002\/rth2.12481","type":"journal-article","created":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T05:23:27Z","timestamp":1613798607000},"page":"356-365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Acquired von Willebrand syndrome in monoclonal gammopathy \u2013 A scoping review on hemostatic management"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6682-4366","authenticated-orcid":false,"given":"Mouhamed Yazan","family":"Abou\u2010Ismail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George M.","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul F.","family":"Bray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5208-3387","authenticated-orcid":false,"given":"Ming Y.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 2","key":"10.1002\/rth2.12481_bb0010","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0049-3848(13)70003-3","article-title":"Diagnosis and treatment of acquired von Willebrand syndrome","volume":"130","author":"Tiede","year":"2012","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12481_bb0015","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1055\/s-0037-1619606","article-title":"Acquired von Willebrand syndrome 2004: International Registry\u2013diagnosis and management from online to bedside","volume":"24","author":"Federici","year":"2004","journal-title":"Hamostaseologie"},{"key":"10.1002\/rth2.12481_bb0020","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2018-04-839480","article-title":"Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications","volume":"132","author":"Fermand","year":"2018","journal-title":"Blood"},{"key":"10.1002\/rth2.12481_bb0025","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1053\/beha.2001.0141","article-title":"Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management","volume":"14","author":"Michiels","year":"2001","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1002\/rth2.12481_bb0030","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00277-016-2650-x","article-title":"Distinct mechanisms account for acquired von Willebrand syndrome in plasma cell dyscrasias","volume":"95","author":"Dicke","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1002\/rth2.12481_bb0035","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1055\/s-2006-949663","article-title":"Immune\u2010mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: therapeutic implications","volume":"32","author":"Michiels","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"10.1002\/rth2.12481_bb0040","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1182\/blood.V92.8.2707","article-title":"Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches","volume":"92","author":"Federici","year":"1998","journal-title":"Blood"},{"key":"10.1002\/rth2.12481_bb0045","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ajh.2830090403","article-title":"Pathogenesis of antibody\u2010induced acquired von Willebrand syndrome","volume":"9","author":"Gan","year":"1980","journal-title":"Am J Hematol"},{"key":"10.1002\/rth2.12481_bb0050","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1182\/blood.V66.3.562.562","article-title":"Comparison of inhibitory and binding characteristics of an antibody causing acquired von Willebrand syndrome: an assay for von Willebrand factor binding by antibody","volume":"66","author":"Fricke","year":"1985","journal-title":"Blood"},{"key":"10.1002\/rth2.12481_bb0055","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1055\/s-0038-1653887","article-title":"High\u2010dose intravenous immunoglobulin delays clearance of von Willebrand factor in acquired von Willebrand disease","volume":"73","author":"van Genderen","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1002\/rth2.12481_bb0060","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1055\/s-0033-1334867","article-title":"Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update","volume":"39","author":"Federici","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"10.1002\/rth2.12481_bb0065","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1182\/blood-2010-11-297580","article-title":"How I treat the acquired von Willebrand syndrome","volume":"117","author":"Tiede","year":"2011","journal-title":"Blood"},{"key":"10.1002\/rth2.12481_bb0070","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: towards a methodological framework","volume":"8","author":"Arksey","year":"2005","journal-title":"Int J Soc Res Methodol"},{"key":"10.1002\/rth2.12481_bb0075","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1478-4505-6-7","article-title":"Asking the right questions: scoping studies in the commissioning of research on the organisation and delivery of health services","volume":"6","author":"Anderson","year":"2008","journal-title":"Health Res Policy Syst"},{"key":"10.1002\/rth2.12481_bb0080","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1111\/hae.12596","article-title":"Cardiovascular disease prevalence and relevance in haemophilia: a scoping review","volume":"21","author":"Rizwan","year":"2015","journal-title":"Haemophilia"},{"key":"10.1002\/rth2.12481_bb0085","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/rth2.12204","article-title":"Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: a scoping review","volume":"3","author":"Yu","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1002\/rth2.12481_bb0090","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.thromres.2020.05.039","article-title":"Thrombosis risk associated with COVID\u201019 infection: a scoping review","author":"Al\u2010Ani","year":"2020","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12481_bb0095","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA\u2010ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1002\/rth2.12481_bb0100","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12481_bb0105","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non\u2010surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12481_bb0110","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non\u2010major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non\u2010surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12481_bb0115","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4065\/mcp.2010.0337","article-title":"Prevalence of monoclonal gammopathy of undetermined significance: a systematic review","volume":"85","author":"Wadhera","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1002\/rth2.12481_bb0120","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.mayocp.2012.06.014","article-title":"Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition","volume":"87","author":"Therneau","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1002\/rth2.12481_bb0125","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12481_bb0130","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1002\/lt.20594","article-title":"High dose intravenous immunoglobulin treatment: mechanisms of action","volume":"11","author":"Boros","year":"2005","journal-title":"Liver Transplant"},{"key":"10.1002\/rth2.12481_bb0135","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/14740338.2018.1513487","article-title":"The safety of bortezomib for the treatment of multiple myeloma","volume":"17","author":"Cengiz Seval","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"10.1002\/rth2.12481_bb0140","doi-asserted-by":"crossref","first-page":"846","DOI":"10.2174\/1568009617666170214104426","article-title":"Immunomodulatory drugs (IMiDs) in multiple myeloma","volume":"17","author":"Raza","year":"2017","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1002\/rth2.12481_bb0145","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/1076029607310920","article-title":"Use of recombinant factor VIIa in inherited and acquired von Willebrand disease","volume":"15","author":"Sucker","year":"2009","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1002\/rth2.12481_bb0150","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/asheducation-2016.1.683","article-title":"New treatment approaches to von Willebrand disease","volume":"2016","author":"Lavin","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"10.1002\/rth2.12481_bb0155","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1111\/hae.13639","article-title":"Intravenous immunoglobulin in patients with acquired Von Willebrand syndrome: A single referral centre experience","volume":"25","author":"Bertolino","year":"2019","journal-title":"Haemophilia"},{"issue":"2","key":"10.1002\/rth2.12481_bb0160","first-page":"143","article-title":"The use of high\u2010dose intravenous gamma\u2010globulin in acquired von Willebrand syndrome","volume":"112","author":"Macik","year":"1988","journal-title":"Arch Pathol Lab Med"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rth2.12481","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/rth2.12481","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922013334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922013334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rth2.12481","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:20:42Z","timestamp":1762863642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037922013334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S2475037922013334"],"URL":"https:\/\/doi.org\/10.1002\/rth2.12481","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acquired von Willebrand syndrome in monoclonal gammopathy \u2013 A scoping review on hemostatic management","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/rth2.12481","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 The Authors. Research and Practice in Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}]}}